Role of mitochondria in nonalcoholic fatty liver disease

Int J Mol Sci. 2014 May 15;15(5):8713-42. doi: 10.3390/ijms15058713.

Abstract

Nonalcoholic fatty liver disease (NAFLD) affects about 30% of the general population in the United States and includes a spectrum of disease that includes simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Significant insight has been gained into our understanding of the pathogenesis of NALFD; however the key metabolic aberrations underlying lipid accumulation in hepatocytes and the progression of NAFLD remain to be elucidated. Accumulating and emerging evidence indicate that hepatic mitochondria play a critical role in the development and pathogenesis of steatosis and NAFLD. Here, we review studies that document a link between the pathogenesis of NAFLD and hepatic mitochondrial dysfunction with particular focus on new insights into the role of impaired fatty acid oxidation, the transcription factor peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), and sirtuins in development and progression of NAFLD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Fatty Acids / chemistry
  • Fatty Acids / metabolism
  • Humans
  • Mitochondria / chemistry
  • Mitochondria / metabolism*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / pathology*
  • Non-alcoholic Fatty Liver Disease / prevention & control
  • Oxidative Stress
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Sirtuin 1 / metabolism
  • Sirtuin 3 / metabolism
  • Transcription Factors / metabolism

Substances

  • Fatty Acids
  • PPARGC1A protein, human
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Transcription Factors
  • Sirtuin 1
  • Sirtuin 3